Beam Therapeutics increases ATM equity offering capacity by $300M to $1.1B

Beam Therapeutics Inc.

Added $300M in capacity to existing $800M at-the-market equity offering with Jefferies.
As of May 10, 2023, ~$772.8M had been sold; remaining capacity increases to ~$327.2M.
Terms unchanged; shares sold via ATM method on Nasdaq under existing shelf registration.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Beam Therapeutics Inc. amended Amendment No. 2 to the Sales Agreement with Jefferies LLC valued at up to $300,000,000 (effective 2023-05-10).

Action: amendment
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $300,000,000
Effective: 2023-05-10

Exact text from the filing

On May 10, 2023, the Company and Jefferies entered into Amendment No. 2 to the Sales Agreement (“Amendment No. 2” and together with the Amended Sales Agreement, the “Further Amended Sales Agreement”) to provide for an increase in the aggregate offering amount under the Amended Sales Agreement, such that as of May 10, 2023, the Company may offer and sell additional shares of Common Stock having an aggregate offering price of up to $300,000,000 (the “Additional Shares” and together with the “Initial Shares”, the “Shares”) under the Further Amended Sales Agreement.

View on SEC.gov

Browse all material agreements →

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-140832

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.